Effect of Therapeutic Education on Pain Intensity and BDNF Levels in Patients With Chronic Pain
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- Universidad Autonoma de Madrid
- Enrollment
- 66
- Locations
- 2
- Primary Endpoint
- Pain Intensity
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The promotion of neuroplasticity in conjunction with strategies for restructuring maladaptive cognitions that largely cause the activation of neural networks that contribute to the perpetuation of pain is therefore a fundamental neurophysiological principle for establishing a neurophysiological basis for pain.
perpetuation of pain, is therefore a fundamental neurophysiological principle for establishing physiotherapy therapeutic to establish therapeutic strategies from physiotherapy that contribute to improve the quality of life of patients with chronic pain. patients with chronic pain.
Based on the theory that neurotrophic factors such as BDNF play a fundamental role in the initiation and or maintenance of hyperexcitability of central neurons in pain, we consider that the levels of this neurotrophic factor, such as BDNF, may have an important role in the perpetuation of pain.
that the levels of this neurotrophic factor may be modified by the application of a therapeutic education protocol, favoring therapeutic education protocol, favoring a reduction in pain intensity.
Investigators
Raúl Ferrer-Peña
Principal Investigator
Universidad Autonoma de Madrid
Eligibility Criteria
Inclusion Criteria
- •males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months
- •patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle
- •not having received physiotherapy treatment for this same process in the last 3 months.
- •ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.
Exclusion Criteria
- •Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.
Outcomes
Primary Outcomes
Pain Intensity
Time Frame: 36 weeks
Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable".
Secondary Outcomes
- Pain Severity Level (GCPS-R)(36 weeks)
- Anxiety and Depression (HADS)(36 weeks)
- Heart rate (HR)(36 weeks)
- BDNF level(36 weeks)
- Oxygen Saturation (SpO2)(36 weeks)
- Quality of life (EQ-5D)(36 weeks)
- Pain Catastrophism (PCS)(36 weeks)